A real-world study of acute and preventive medication use, adherence, and persistence in patients prescribed fremanezumab in the United States

por Krasenbaum, Lynda J., Pedarla, Vasantha L., Thompson, Stephen F., Tangirala, Krishna, Cohen, Joshua M., Driessen, Maurice T.
Publicado 2022

Adverse Events Reported with Therapies Targeting the CGRP Pathway During the First 6 Months Post-launch: A Retrospective Analysis Using the FDA Adverse Events Reporting System

por Silberstein, Stephen D., Reshef, Shoshana, Cohen, Joshua M., Gandhi, Sanjay, Seminerio, Michael, Ramirez Campos, Verena, Kessler, Yoel, Thompson, Stephen F., Blumenfeld, Andrew
Publicado 2022

Real-world effectiveness of fremanezumab in migraine patients initiating treatment in the United States: results from a retrospective chart study

por Driessen, Maurice T., Cohen, Joshua M., Patterson-Lomba, Oscar, Thompson, Stephen F., Seminerio, Michael, Carr, Karen, Totev, Todor I., Sun, Rochelle, Yim, Erica, Mu, Fan, Ayyagari, Rajeev
Publicado 2022

Real-world effectiveness after initiating fremanezumab treatment in US patients with episodic and chronic migraine or difficult-to-treat migraine

por Driessen, Maurice T., Cohen, Joshua M., Thompson, Stephen F., Patterson-Lomba, Oscar, Seminerio, Michael J., Carr, Karen, Totev, Todor I., Sun, Rochelle, Yim, Erica, Mu, Fan, Ayyagari, Rajeev
Publicado 2022